- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| BIOMED LUBLIN Aktie jetzt für 0€ handeln |
0 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVONESIS | 54,50 | +0,48 % | Novonesis (Novozymes A/S): Trading by management and close relations of management | ||
| GENMAB | 194,45 | +0,46 % | Genmab A/S (GMAB): Among 12 High Growth Large Cap Stocks to Buy Now | ||
| ARBUTUS BIOPHARMA | 3,294 | +0,61 % | Arbutus Biopharma Corporation: Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B | Significantly greater mean declines in HBsAg levels (p 23% of participants receiving imdusiran, VTP-300 and low-dose nivolumab reached HBsAg loss by Week 48 WARMINSTER, Pa. and OXFORD, United Kingdom... ► Artikel lesen | |
| MOLECULIN BIOTECH | 2,360 | 0,00 % | Moleculin Biotech erzielt Fortschritte im Annamycin-AML-Studienprotokoll | ||
| VERICEL | 53,50 | -1,83 % | Vericel Corporation: Vericel Reports Third Quarter 2024 Financial Results | Total Revenue Growth of 27% to $57.9 Million Gross Margin of 72% and Adjusted EBITDA Growth of 84% Full-Year Profitability Guidance Raised FDA Approval and Commercial Launch of MACI Arthro in Third... ► Artikel lesen | |
| BIOXCEL THERAPEUTICS | 0,530 | -4,64 % | BioXcel Therapeutics-Aktie erreicht 52-Wochen-Tief bei 0,50 US-Dollar | ||
| SENSEI BIOTHERAPEUTICS | 0,470 | +1,29 % | Sensei Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights | - SNS-101 Phase 1/2 dose expansion clinical data expected in the first half of 2025 - - Organizational restructuring to focus resources on advancing the clinical development of SNS-101 - ... ► Artikel lesen | |
| MUSTGROW BIOLOGICS | 1,215 | -0,41 % | MustGrow Biologics Corp.: MustGrow Provides 2024 Pipeline Update | MustGrow transitions from R&D to commercialization.TerraSanteTM biofertility product manufacturing and sales has commenced, with potential initial sales ramp-up in 2025 and 2026.Commercialization of... ► Artikel lesen | |
| REGENXBIO | 9,200 | +0,55 % | Regenxbio eyes 2026 filing for Duchenne muscular dystrophy gene therapy | ||
| AKEBIA | 1,681 | -1,35 % | Akebia Therapeutics, Inc.: Akebia Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights | Vafseo® (vadadustat) on track for U.S. market availability expected in January 2025
Over 300,000 patients, representing approximately 60% of dialysis patient... ► Artikel lesen | |
| FENNEC PHARMACEUTICALS | 4,340 | +10,71 % | Fennec Pharmaceuticals Inc.: Fennec Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update | ~ Achieved Third Quarter 2024 Net Product Sales of $7.0 Million ~ ~ Increasing Momentum and Successful Reimbursement in the Adolescent and Young Adult (AYA) Segment Following Strategic Investments... ► Artikel lesen | |
| REVANCE THERAPEUTICS | 3,460 | -4,42 % | Revance Therapeutics gains as Crown Labs further extends tender offer | ||
| ZEVRA THERAPEUTICS | 8,300 | -2,35 % | ZVRA-Aktie erreicht 52-Wochen-Hoch bei 9,09 US-Dollar | ||
| CORVUS PHARMACEUTICALS | 7,800 | -0,38 % | Corvus Pharmaceuticals, Inc.: Corvus Pharmaceuticals Announces New Preclinical Data Highlighting Potential of Soquelitinib to Treat Systemic Sclerosis | Adds to growing body of evidence supporting the potential of ITK inhibition as a novel therapeutic for the treatment of a wide range of immune diseases Data will be presented in a poster at ACR Convergence... ► Artikel lesen | |
| CARTESIAN THERAPEUTICS | 16,700 | 0,00 % | Cartesian Therapeutics, Inc.: Cartesian Therapeutics to Present Updated Data from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis at the 2nd Annual Cell Therapy for Autoimmune Disease Summit |
Das Unternehmen BIOMED-LUBLIN WYTWORNIA SUROWIC I SZCZEPIONEK SA kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,004 (-0,47 %) liegt der Kurs bei 0,856 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIOMED-LUBLIN WYTWORNIA SUROWIC I SZCZEPIONEK SA finden Sie auf Wallstreet Online.
